Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERTHENA-Lung01
NCT04619004Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of patritumab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective Response Rate at 21 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04619004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04619004.